z-logo
open-access-imgOpen Access
Broadening the use of antiretroviral therapy: the case for feline leukemia virus
Author(s) -
Louis M. Mansky,
Willie M Greggs,
Christine C. Clouser,
Steven Patterson
Publication year - 2011
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s17731
Subject(s) - medicine , feline leukemia virus , virology , indinavir , integrase , integrase inhibitor , retrovirus , antiretroviral therapy , gammaretrovirus , feline immunodeficiency virus , reverse transcriptase , immunology , drug , virus , viral load , human immunodeficiency virus (hiv) , pharmacology , lentivirus , viral disease , biology , polymerase chain reaction , biochemistry , gene
Antiretroviral drugs have saved and extended the lives of millions of individuals infected with HIV. The major classes of anti-HIV drugs include reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, and entry/fusion inhibitors. While antiretroviral drug regimens are not commonly used to treat other types of retroviral infections, there are instances where there is a perceived need for re-evaluation of the benefits of antiretroviral therapy. One case in point is that of feline leukemia virus (FeLV), an infection of companion felines. While vaccines exist to prevent FeLV infection and spread, they have not eliminated FeLV infection. For FeLV-infected felines and their human companions, antiretroviral therapy would be desirable and of practical importance if good options were available. Here, we discuss FeLV biology and current treatment options, and propose that there is a need for antiretroviral treatment options for FeLV infection. The comparative use and analysis of antiretroviral therapy can provide new insights into the mechanism of antiretroviral drug action.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom